Updated:
RenovoRx
RenovoRx was established in 2015 by Dr. Shaun Bagai, a cardiothoracic surgeon who previously founded several medical-device companies.
RenovoRx
RenovoRx was established in 2015 by Dr. Shaun Bagai, a cardiothoracic surgeon who previously founded several medical-device companies. The firm functions as a bio-pharmaceutical and medical-device hybrid, with its lead asset being the RenovoCath catheter system. This device is designed to deliver chemotherapy directly into the arterial supply of a solid tumor, a method intended to increase local drug concentration while reducing systemic exposure and side effects. The underlying wealth origin is not tied to a single-family fortune; the company is publicly traded on the Nasdaq under the ticker RNXT and funded through institutional life-sciences investors. The company's primary therapeutic focus is locally advanced pancreatic cancer, a disease with notoriously poor outcomes. Its lead product candidate, RenovoGem, pairs the RenovoCath delivery system with gemcitabine for intra-arterial administration. The firm completed a $15.4 million registered direct offering in January 2024 to fund an ongoing Phase III clinical trial called TIGeR-PaC, which compares its therapy to standard-of-care systemic chemotherapy. Pipeline interests also stretch into other solid tumors including bile duct cancer and lung cancer. RenovoRx operates from Los Altos, California. The senior team includes Chief Medical Advisor Dr. Robert Spiegel, a former senior executive at Schering-Plough, and Dr. Ramachandra Tummala, a vascular neurosurgeon. May 2024: Announced a two-year collaboration with Imugene Limited to evaluate its therapy in combination with an oncolytic virus for bile duct cancer (per GlobeNewswire, May 2024). The firm does not maintain a philanthropic foundation, club membership, or adjacent real-asset arm in publicly disclosed records. RenovoRx is structurally distinct for operating a hybrid drug-device pivotal trial under a single 510(k)-cleared catheter platform. This attempts to reduce the regulatory risk profile typical of early-stage oncology therapeutics by anchoring a drug trial to an already-cleared delivery device.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Los Altos
Corporate office
Los Altos, CA, United States
Principals
Shaun R. Bagai
Chief Executive Officer
Robert J. Spiegel
Chief Medical Advisor
Ramachandra P. Tummala
Chief Medical Officer (Interventional Radiology)
Sector focus
Frequently asked questions
What is RenovoRx's lead product and how does it work?
The lead product candidate is RenovoGem, which combines the RenovoCath dual-balloon catheter with the chemotherapy drug gemcitabine. The catheter is threaded into the artery supplying a solid tumor, and the drug is delivered directly to the tumor bed. This method aims to maximize local drug concentration while minimizing systemic toxicity compared to intravenous chemotherapy.
Is RenovoRx a medical-device company or a biotech firm?
It operates as both. The RenovoCath catheter has 510(k) clearance from the FDA as a medical device for peripheral arterial infusion. The firm's lead clinical program, the TIGeR-PaC trial, is evaluating RenovoGem as a drug-device combination therapy, which is a distinct regulatory category under the FDA's jurisdiction.
What is the status of the TIGeR-PaC clinical trial?
TIGeR-PaC is a randomized multi-center Phase III clinical trial comparing RenovoGem to standard-of-care systemic chemotherapy for locally advanced pancreatic cancer. The trial completed an interim analysis in early 2023, and enrollment is ongoing. The study uses overall survival as its primary endpoint.
How does the firm fund its operations?
RenovoRx is a publicly traded company listed on the Nasdaq Capital Market under the ticker RNXT. It funds its clinical programs through a combination of public equity raises, registered direct offerings, and institutional life-sciences investors. A $15.4 million registered direct offering closed in January 2024.
Who leads the clinical and regulatory development at RenovoRx?
Dr. Robert J. Spiegel serves as Chief Medical Advisor. He is a former Chief Medical Officer at Schering-Plough and has deep experience in oncology drug development. The interventional radiology expertise is led by Dr. Ramachandra Tummala, the Chief Medical Officer for Interventional Radiology, who is a practicing vascular neurosurgeon.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: